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Abstract
Background: Advanced ovarian cancer is the leading non-breast gynaecologic cause of malignant
pleural effusion. Aim of this study was to assess the efficacy of mitoxantrone sclerotherapy as a
palliative treatment of malignant pleural effusions due to ovarian cancer.
Methods: Sixty women with known ovarian cancer and malignant recurrent symptomatic pleural
effusion were treated with chest tube drainage followed by intrapleural mitoxantrone
sclerotherapy. Survival, complications and response to pleurodesis were recorded. The data are
expressed as the mean ± SEM and the median.
Results: The mean age of the entire group was 64 ± 11,24 years. The mean interval between
diagnosis of ovarian cancer and presentation of the effusion was 10 ± 2,1 months. Eighteen patients
(30%) had pleural effusion as the first evidence of recurrence. The mean volume of effusion drained
was 1050 ± 105 ml and chest tube was removed within 4 days in 75% of patients. There were no
deaths related to the procedure. Side effects of chemical pleurodesis included fever (37–38,5°C)
chest pain, nausea and vomiting. At 30 days among 60 treated effusions, there was an 88% overall
response rate, including 41 complete responses and 12 partial responses. At 60 days the overall
response was 80% (38 complete responses and 10 partial responses). The mean survival of the
entire population was 7,5 ± 1,2 months.
Conclusions: Mitoxantrone is effective in the treatment of malignant pleural effusion secondary
to ovarian cancer without causing significant local or systemic toxicity.
Background
Cancer accounts for 40% of all pleural effusions, espe-
cially in patients over 50 years old [1]. Bronchogenic and
breast cancer account for 75% of malignant pleural effu-
sions, with the remaining 25% represented by a cross-sec-
tion of other neoplastic diseases [2].
Approximately two thirds of malignant pleural effusions
occur in women because of the strong association with
breast and ovarian cancer [3]. Advanced ovarian cancer is
the leading non-breast gynaecologic cause of malignant
pleural effusion. Pleural metastases were found in 48% of
women who died from ovarian cancer [4].
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The general approach to managing malignant effusions is
determined by symptoms, performance status of the
patient, expected survival and response of the known pri-
mary tumor to systemic treatment. Intervention options
range from observation in the case of asymptomatic effu-
sions through simple thoracentesis to more invasive
methods such as thoracoscopy, pleuroperitoneal shunting
and pleurectomy. In patients with reasonable survival
expectancy and good performance status every attempt
should be made to prevent recurrence of the effusion.
Intercostal tube drainage with instillation of a sclerosing
agent, resulting in the obliteration of the pleural space, is
the most widely used method to control recurrent symp-
tomatic malignant pleural effusions.
Aim of this study was to study 60 patients with ovarian
cancer who had a pleural effusion as a direct consequence
of metastatic disease and to assess the efficacy of mitox-
antrone as a sclerosing agent.
Methods
Over an 8-year period (1996–2003), all patients with
known ovarian malignancy and recurrent symptomatic
malignant pleural effusion referred to Thoracic Surgery
Department of Theagenio Cancer Hospital for drainage
and sclerotherapy, were eligible to participate in this
study. This study was approved by the Theagenio Cancer
Research Ethics Committee and patients were included
after giving their informed consent.
All patients satisfied the following eligibility criteria:
1. Known ovarian malignancy.
2. Recurrent symptomatic malignant pleural effusion. The
diagnosis established by positive pleural fluid cytology on
thoracentesis or positive pleural biopsy.
3. Evidence of expansion of the lung after fluid drainage
and abscence of bronchial obstruction and/or fibrosis pre-
venting lung expansion.
4. No previous intrapleural therapy.
5. Predicted survival of >1 month.
Patients were ineligible if they had a history of cardiac dis-
ease, obstructive jaundice or surgery within the previous
month. No patient had systemic chemotherapy immedi-
ately prior to or during the first 30-day interval following
sclerotherapy. Sixty women fulfilled the above eligibility
criteria.
Pretreatment assessment was performed during admis-
sion and included history and physical examination, full
blood count, liver biochemistry, electrocardiogram, a pre-
drainage base line posteroanterior and lateral chest radio-
graph and other imaging as clinically indicated.
A chest tube (28–32 F) was inserted into the midaxillary
line through the 5th or 6th intercostal space under local
anesthesia and in some case additional intravenous ben-
zodiazepines and/or narcotics. The pleural effusion was
drained to dryness initially by gravity and followed if nec-
essary by suction from a wall-mounted suction pump
using a pressure of 20 cm H2O usually for 12–24 hours to
achieve complete drainage of the effusion and lung re-
expansion. Daily tube outputs were recorded and when
drainage fell below 100 ml in a 24 h period, posteroante-
rior and lateral chest radiographs were obtained to assure
that the fluid had been sufficiently evacuated, there were
no loculated collections and the lung had fully re-
expanded. Then the patients were eligible for pleurodesis.
Fifty ml of normal saline solution containing 2 mg/kg
lidocaine were infused through the chest tube. After 15
minutes, a pleurodesis solution containing a mixture of
40 mg mitoxantrone and 20 ml normal saline was infused
into the pleural cavity, after which the tube was clamped
for 2 hours, while the patients changed position (rotated
90°) every 15 minutes. The tube then was re-opened. If
the post-sclerotherapy drainage was <100 ml per day
thetube was removed.
Complications related to the procedure were recorded.
Post-sclerotherapy posteroanterior and lateral chest radio-
graphs were obtained immediately after tube removal in
order to be compared with others obtained 30 and 60
days later.
The radiographic response was determined on poster-
oanterior and lateral chest radiographs by observing the
level of fluid meniscus overlying the costophrenic or ver-
tebrophrenic angles and was determined as follows: com-
plete response(CR) – no re-accumulation of pleural fluid,
partial response (PR) – fluid recurrence less than 50% of
the original level without symptoms or not requiring
repeat drainage, progressive disease (PD) – re-accumula-
tion to or above the original level with symptoms and
requiring repeat drainage.
Survival was calculated from the day of diagnosis of pleu-
ral effusion to the day of death or to the last day of follow
up if alive.
The data are expressed as the mean ± SEM and the median.
Results
Sixty women were included in this study. The mean age of
the entire group was 64 ± 11,24 years. The intervalBMC Palliative Care 2004, 3:4 http://www.biomedcentral.com/1472-684X/3/4
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between diagnosis of ovarian cancer and the development
of a subsequent malignant pleural effusion ranged from 1
to 36 months (mean: 10 ± 2,1 months). Fifty one patients
(85%) had unilateral effusion and 9 (15%) bilateral. His-
tology, degree of differentiation and TNM stage [5] at the
time of diagnosis of the primary tumor are shown in Table
1.
Eigtheen patients (30%) had pleural effusion as the first
manifestation of recurrent disease, whereas 42 patients
(70%) were already diagnosed as having local or distant
spread before the onset of pleural effusion. These 42
patients with preexisting metastases showed a variable
pattern of secondary spread. Eighteen patients had paren-
chymal liver metastases and intraabdominal lymph
nodes, 11 patients had liver metastases only, 8 had syn-
chronous lung and liver metastases, 2 had lung metastases
only, 1 patient had umbilical nodule, 1 had anterior wall
abdominal wall infiltration and 1 had brain metastases.
The mean volume of effusion drained was 1050 ± 105 ml
(range: 450–1500 ml). Chest tube was removed within 4
days in 75% of patients (range: 3 – 10 days).
There were no deaths related to the thoracostomy proce-
dure. One patient experienced vasovagal reflex during the
procedure with systemic hypotension and intense pleu-
ritic pain. Hypotension was treated with intravenous flu-
ids and the pain was controlled with narcotics. This
episode lasted 20 minutes. The patient recovered without
incident.
The most frequent complications related to pleurodesis
were fever (temperature > 37°C), chest pain, nausea and
vomiting (Table 2).
Three patients died within 1 month of pleurodesis due to
rapid progression metastatic disease. At 30 days, 57
patients were alive and 41 out of them had a complete
response and 12 had a partial response. The overall
response to chemical pleurodesis with mitoxantrone was
88% (53/57 patients). Four patients had progressive dis-
ease and revealed reaccumulation of fluid to or above the
original level.
At 60 days 52 patients were alive and 38 out of them had
a complete response and 10 had a partial response. The
overall response was 80% (complete response 38/60
patients – 63,4%, partial response 10/60 patients –
16,6%). Follow up ranged from 10 days to 38 months
with a mean of 10 ± 1,36 months. Eight patients out of the
41, who initially had complete response developed later
recurrent pleural effusion and needed again tube thora-
costomy and a second attempt of chemical pleurodesis.
Table 1: Histology, degree of differentiation and TNM stage at the time of diagnosis of the primary tumor.
Histology Number of patients (n:60) Percentage
Serous cystadenocarcinoma 38 63,3%
Mucinous adenocarcinoma 8 13,4%
Mixed 4 6,7%
Clear cell 3 5%
Endometrioid 2 3,4%
Unknown 5 8,4%
Degree of differentiation
G1 16 26,7%
G2 18 30%
G3 26 43,3%
TNM stage
I 8 13,3%
II 18 30%
III 22 36,7%
IV 12 20%
Table 2: Complications related to chemical pleurodesis with 
mitoxantrone
Complications Number of patients (n:60)
None 31 (51,6%)
Fever 16 (26,6%)
Chest pain 12 (20%)
Nausea 11 (18,3%)
Vomiting 9 (15%)
Diarrhea 4 (6,6%)
Alopecia 1 (1,6%)
Skin Rash 1 (1,6%)
Dyspnea 1 (1,6%)
Myelosuppression 1 (1,6%)BMC Palliative Care 2004, 3:4 http://www.biomedcentral.com/1472-684X/3/4
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The mean survival of the entire study population was 7,5
± 1,2 months (median: 5,4 months).
Discussion
Management of malignant pleural effusions depends on
the underlying malignancy, extent of disease, potential
effectiveness of treatment and performance status. In
patients with lymphoma, small cell lung cancer or germ
cell neoplasms, pleural effusions may be controlled ini-
tially by systemic therapy alone. In patients with meta-
static breast or non small cell lung carcinoma, local
palliative treatment is often required. Since malignant
pleural effusions are frequently a preterminal event with a
30-day mortality rate of 29 to 50%, treatment is directed
toward symptomatic relief with minimal discomfort,
inconvenience and cost [6-8].
Local treatment options include repeated thoracenteses,
chest tube drainage with sclerotherapy, pleuroperitoneal
shunt or pleurectomy. Repeated thoracentesis is usually a
temporizing measure and carries the risk for pneumotho-
rax and pleural infection [9]. Inpatient drainage with
large-bore tubes (28–36 F) is effective, with variable 30-
day success rates reported between 55% and 95% [10].
For this reason, large-bore tube thoracostomy with sclero-
therapy has become the most common palliative treat-
ment for malignant effusions. It has to be mentioned that
recent studies have shown that small drainage catheters
(10 to 14 F) are as effective as large bore chest tubes in the
treatment of malignant effusions [11]. Using imaging
guidance, small tubes can be placed into loculated collec-
tions, are well tolerated and have complication rates less
than the larger tubes [12].
Pleural effusion due to metastatic ovarian cancer is a fre-
quent phenomenon and as shown in our study it can
occur as early as one month or as late as 36 months with
a median of 8,5 months. This is in complete accord with
the study of Cheng et al who found a median interval of 9
months [13]. When effusion occurs within 1 month of
diagnosis of ovarian cancer, one is probably dealing with
IV stage and clinical experience has proved that these
patients have an especially poor prognosis.
Numerous sclerosing agents have been used to treat
malignant pleural effusions. Until recently, tetracycline
was the most commonly used sclerosing agent with
response rates ranging from 25 to 100% [14,15]. Because
the intravenous form of tetracycline is no longer available,
doxycycline has been proposed as an alternative.
Bleomycin has been studied extensively as a sclerosing
agent [16,17]. Goff et al succesfully used bleomycin intra-
pleurally to treat malignant pleural effusions from gyne-
cological cancer with a 71% overall response at 30 days
and minimal adverse reactions. Intrapleural instillation is
usually well tolerated but a few patients may report mild
fever or transient nausea. Pleuritic pain and rigors are
rarely reported side effects. This relative lack of systemic
toxicity is likely due to limited absorption of bleomycin
(approximately 40%) of the pleural cavity [18]. At 30 days
bleomycin has been reported to be superior to tetracycline
[19].
Talc has proved to be one of the most effective sclerosing
agents for treating malignant pleural effusions. Talc causes
severe pleuritis resulting in effective pleurodesis but can
worsen dyspnea and can result in respiratory failure [20].
Other complications associated with talc pleurodesis
include fever, acute pneumonitis, granulomatous pneu-
monitis and empyema [21]. Talc is instilled either as a
slurry via chest tube or insufflated via thoracoscope.
Many other chemotherapeutic agents such as doxoru-
bicin, cisplatin and cytarabine combination, etoposide,
fluorouracil and mitomycin have been used for sclero-
therapy. In addition radioactive isotopes, corynebacte-
rium parvum, interferon and recombinant interleukin-2
have been instilled in the pleural space for treatment of
malignant pleural disease. Response rate have been varia-
ble and less than optimal. Side effects are not inconse-
quential and thus none of these agents have gained
widespread use [22].
Mitoxantrone is a synthetic anthracenedione which has
been demonstrated to be effective in the treatment of peri-
toneal and pleural effusion. From a pharmacological
point of view, mitoxantrone may be an especially appro-
priate choice due to its higher molecular weight and
polarity since this may be factor important in prolonging
contact with the pleura. The mechanism of intrapleural
action of mitoxantrone has not yet been established. Both
the inflammatory and antineoplastic activity of mitox-
antrone intrapleurally have been described [23,24].
Our findings are consistent with the findings of others. In
a prospective study in 18 patients, Musch et al [25]
reported a 30-day success rate of 75%. A comparative
study including bleomycin and mitoxantrone showed
almost an equal 30-day response of 64% and 67% respec-
tively [26]. Van Belle et al [27] had an overall 30-day
response of successful pleurodesis of 67% in patients with
ovarian cancer (2/3 patients). Morales et al [28] treated a
group of 21 patients with malignant pleural effusions,
with instillation of mitoxantrone with a 100% response
and no toxic effects.
There is only one study which proved mitoxantrone inef-
fective. Groth et al. [29] presented a prospective rand-
omized trial on the treatment of malignant pleuralBMC Palliative Care 2004, 3:4 http://www.biomedcentral.com/1472-684X/3/4
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effusions with intrapleural mitoxantrone versus placebo
(pleural tube alone with instillation of isotonic NaCl).
Their data suggest no statistically significant difference
between the two arms with respect to response and
response duration.
Our study confirmed the majority of previous reports that
mitoxantrone is an effective agent in controlling recurrent
malignant pleural effusions. The overall 30-day response
rate was 88%. Side effects were mild and rare.
To develop new treatment plans for the management of
pleural effusions, one must consider several requirements.
First, no treatment regimen should exacerbate patients'
symptoms, since palliation is the main aim. Second, seri-
ously ill patients should not be subjected to procedures
associated with high mortality and morbidity. Third, since
about half the patients with pleural effusion will have no
other clinically apparent metastases, treatment should be
local rather than systemic. To be successful, the local treat-
ment has to be effective and given at the first sign of the
effusion, because inadequate or delayed treatment may
eliminate the possibility of any subsequent therapy being
effective, by producing loculation of the effusion.
Conclusions
Pleural effusion often occurs during the course of ovarian
cancer. Chemical pleurodesis via bedside thoracostomy
has been shown to be effective and has become a com-
mon therapeutic approach. Using this approach we found
mitoxantrone to be highly effective at controlling malig-
nant pleural effusions and decreasing the associated
symptoms of dyspnea and pain. Our data justify further
studies in a controlled setting to elucidate the biological
action and prognostic relevance of mitoxantrone in the
treatment of malignant pleural effusions and to compare
this agent with other treatment procedures.
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